ITOS - ASCO 2022: What investors should pay attention to at the year's biggest medical meeting

The 2022 American Society of Clinical Oncology Annual Meeting that begins June 3 is perhaps is the most eagerly anticipated medical meeting of the year. Thousands of abstracts and studies will be presented from pharma and biotech companies large and small. Some of the results are eagerly anticipated and have the potential to materially impact a company's stock. Here's a look at some presentations to look out for. AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu (trastuzumab) in HER2-low breast cancer. Data from the DESTINY-Breast04 study is in breast cancer patients whose tumors express low levels of the protein HER2. This group accounts for more than half of all breast cancer patients. Should the data be strong in this setting, it could provide a boon for Enhertu as these patients typically can't use other HER2 therapies. This includes Roche's (OTCQX:RHHBY) Herceptin (trastuzumab) and Perjeta (pertuzumab), and Seagen's (SGEN) Tukysa (tucatinib). In February, the

For further details see:

ASCO 2022: What investors should pay attention to at the year's biggest medical meeting